Table 2. Subgroup analysis of pooled interaction hazard ratio comparing current/former with never smokers by therapy line, study drugs and histological subtypes.
| Subgroups | OS_current/former versus never | PFS_current/former versus never | |||||
|---|---|---|---|---|---|---|---|
| No. of trials | Pooled interaction HR (95% CI) | Inter-group heterogeneity | No. of trials | Pooled interaction HR (95% CI) | Inter-group heterogeneity | ||
| Lines | |||||||
| >1st line | 5 | 0.80 (0.71, 0.91) | I2=0.0%; P=0.53 | 3 | 0.78 (0.44, 1.38) | I2=0.0%; P=0.92 | |
| 1st line | 6 | 0.76 (0.69, 0.85) | 5 | 0.81 (0.46, 1.44) | |||
| Drugs | |||||||
| Beva | 1 | 0.66 (0.48, 0.90) | I2=27.2%; P=0.22 | 3 | 0.63 (0.34, 1.16) | I2=45.3%; P=0.14 | |
| Nivo | 3 | 0.80 (0.64, 1.01) | 3 | 1.30 (0.65, 2.59) | |||
| Atez | 2 | 0.80 (0.71, 0.89) | 1 | 0.63 (0.35, 1.12) | |||
| Pemb | 2 | 0.58 (0.39, 0.85) | 1 | 0.43 (0.23, 0.81) | |||
| Avel | 1 | 1.13 (0.57, 2.25) | |||||
| Ipil | 1 | 0.93 (0.74, 1.16) | |||||
| Durv | 1 | 0.63 (0.43, 0.92) | |||||
| Histological subtypes | |||||||
| NSCLC | 6 | 0.77 (0.67, 0.87) | I2=36.0%; P=0.21 | 4 | 1.00 (0.66, 1.54) | I2=39.9%; P=0.22 | |
| Non-squamous | 4 | 0.72 (0.60, 0.87) | 4 | 0.60 (0.30, 1.20) | |||
| Squamous | 1 | 0.93 (0.74, 1.16) | |||||
Atez, atezolizumab; Avel, avelumab; Beva, bevacizumab; Durv, durvalumab; Ipil, ipilimumab; Nivo, nivolumab; OS, overall survival; Pemb, pembrolizumab; PFS, progressive-free survival.